Intravitreal Bevacizumab for Radiation-Induced Cystoid Macular Oedema in Patients with Nasopharyngeal Carcinoma: A Clinical Series

2013 ◽  
Vol 229 (4) ◽  
pp. 208-211 ◽  
Author(s):  
Visvaraja Subrayan ◽  
Keat Ween Khaw ◽  
Mohammadreza Peyman ◽  
Adrian Choon Aun Koay ◽  
Iqbal Tajunisah
Keyword(s):  
Nasopharyngeal Carcinoma ◽  
Macular Oedema ◽  
Intravitreal Bevacizumab ◽  
Cystoid Macular Oedema ◽  
Clinical Series ◽  
Radiation Induced

scholarly journals Intravitreal Bevacizumab and Triamcinolone for Treatment of Cystoid Macular Oedema Associated with Chronic Myeloid Leukaemia and Imatinib Therapy

2015 ◽  
Vol 2015 ◽  
pp. 1-3 ◽  
Author(s):  
Eric K. Newcott ◽  
Abdallah A. Ellabban ◽  
Shokufeh Tavassoli ◽  
Ahmed Sallam
Keyword(s):  
Chronic Myeloid Leukaemia ◽  
Myeloid Leukaemia ◽  
Macular Oedema ◽  
Intravitreal Bevacizumab ◽  
Imatinib Therapy ◽  
Cystoid Macular Oedema ◽  
Imatinib Treatment ◽  
Intravitreal Triamcinolone ◽  
Fellow Eye

Purpose.To evaluate the efficacy of intravitreal bevacizumab and triamcinolone in the treatment of cystoid macular oedema in a case with chronic myeloid leukaemia on imatinib treatment.Methods.We treated a 78-year-old man with bilateral cystoid macular oedema with intravitreal triamcinolone and subsequent bevacizumab in one eye and intravitreal bevacizumab, alone, in the fellow eye.Results.Serial intravitreal bevacizumab with and without triamcinolone treated cystoid macular oedema in both eyes and improved the vision.Conclusion.Intravitreal bevacizumab and triamcinolone could be viable options to treat cystoid macular oedema due to chronic myeloid leukaemia and imatinib therapy.

scholarly journals Pigmented paravenous retinochoroidal atrophy associated with unilateral cystoid macular oedema

2019 ◽  
Vol 12 (8) ◽  
pp. e230633 ◽  
Author(s):  
Ricardo Figueiredo ◽  
Tiago Morais Sarmento ◽  
João Garrido ◽  
António Ramalho
Keyword(s):  
Macular Oedema ◽  
Intravitreal Bevacizumab ◽  
Cystoid Macular Oedema ◽  
Visual Response ◽  
Blurred Vision ◽  
Visual Field Test ◽  
Pigmented Paravenous Retinochoroidal Atrophy ◽  
Funduscopic Examination ◽  
Electrophysiological Examination ◽  
Topical Dorzolamide

A 65-year-old man was referred to our department with complaints of blurred vision in the left eye. Funduscopic examination revealed areas of retinochoroidal atrophy along the retinal veins bilaterally and bone spicule pigmentation along the nasal and superior temporal venous branches, as well as macular oedema in the left eye. Fluorescein angiography, visual field test, optical coherence tomography and electrophysiological examination were performed, and results were compatible with the diagnosis of pigmented paravenous retinochoroidal atrophy (PPRCA). Treatment with topical dorzolamide and intravitreal bevacizumab in the left eye resulted in poor anatomical and visual response. There is scarce documentation of macular involvement with non-inflammatory unilateral cystoid macular oedema in PPRCA in the literature. Further investigation is required to elucidate the pathogenesis of PPRCA and to properly manage these patients.

scholarly journals Macular Oedema Related to Idiopathic Macular Telangiectasia Type 1 Treated with Dexamethasone Intravitreal Implant (Ozurdex)

2014 ◽  
Vol 2014 ◽  
pp. 1-5
Author(s):  
Mohamed Loutfi ◽  
Thomas Papathomas ◽  
Ahmed Kamal
Keyword(s):  
Visual Acuity ◽  
Macular Oedema ◽  
Intravitreal Bevacizumab ◽  
Visual Disturbance ◽  
Cystoid Macular Oedema ◽  
Dexamethasone Intravitreal Implant ◽  
Macular Telangiectasia ◽  
Intravitreal Implant ◽  
The Right

A 65-year-old female presented with visual disturbance in her right eye lasting for over 2 months. Following investigations, she was diagnosed with MacTel type 1 in the right eye. Visual symptoms were refractory to initial treatment with intravitreal bevacizumab and thereafter intravtireal triamicinolone. The patient was then treated with Ozurdex, following which central macular thickness (CMT) decreased (from 397 μm to 286 μm) and visual acuity deteriorated (from logMAR 0.48 to 0.59). At 14 weeks posttreatment with Ozurdex, a recurrence of cystoid macular oedema (CMO) was observed. Following a second Ozurdex, visual acuity improved (from logMAR 0.7 to 0.64) and CMT decreased (from 349 μm to 279 μm). An additional recurrence of CMO was observed at eighteen weeks following the second Ozurdex. Following a third Ozurdex injection visual acuity deteriorated (from logMAR 0.74 to 0.78) and CMT decreased (from 332 μm to 279 μm).Conclusion. Treatment of macular oedema secondary to MacTel with Ozurdex demonstrated promising anatomical outcomes. However, visual outcomes continued to gradually deteriorate.

scholarly journals Cystoid macular oedema in Cogans syndrome-a case report

Cases Journal ◽  
2008 ◽  
Vol 1 (1) ◽  
pp. 339 ◽  
Author(s):  
Anupama Pherwani ◽  
Shveta Bansal ◽  
Shailesh Agrawal ◽  
Timothy Gillow
Keyword(s):  
Case Report ◽  
Macular Oedema ◽  
Cystoid Macular Oedema
Sign in / Sign up

Export Citation Format

Share Document